%	O
%	O
TITLE	O

Association	O
Between	O
Hepatitis	O
C	O
Virus	O
and	O
Head	O
and	O
Neck	O
Cancers	O
.	O

%	O
%	O
ABSTRACT	O

Hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
infection	O
is	O
associated	O
with	O
hepatocellular	O
carcinoma	O
and	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
.	O

In	O
2009	O
,	O
MD	O
Anderson	O
established	O
the	O
first	O
US	O
clinic	O
for	O
treating	O
HCV	O
-	O
infected	O
cancer	O
patients	O
,	O
where	O
we	O
observed	O
an	O
unexpectedly	O
large	O
number	O
of	O
patients	O
with	O
head	O
and	O
neck	O
cancers	O
(	O
HNCs	O
)	O
.	O

We	O
sought	O
to	O
determine	O
whether	O
HCV	O
is	O
associated	O
with	O
HNCs	O
.	O
In	O
this	O
case	B-Study_Type
-	I-Study_Type
control	I-Study_Type
study	I-Study_Type
,	O
medical	O
records	O
of	O
cancer	B-Study_Cohort
patients	I-Study_Cohort
tested	I-Study_Cohort
for	I-Study_Cohort
HCV	I-Study_Cohort
antibodies	I-Study_Cohort
at	O
our	O
center	O
from	O
2004	B-Study_Time
through	I-Study_Time
2014	I-Study_Time
were	O
identified	O
.	O

Case	O
subjects	O
had	O
new	O
-	O
onset	O
primary	O
oropharyngeal	O
or	O
nonoropharyngeal	O
(	O
oral	O
cavity	O
,	O
nasopharynx	O
,	O
hypopharynx	O
,	O
or	O
larynx	O
)	O
HNCs	O
.	O

Control	O
subjects	O
had	O
smoking	O
-	O
associated	O
(	O
lung	O
,	O
esophagus	O
,	O
or	O
urinary	O
bladder	O
)	O
cancers	O
.	O

Biopsy	B-HPV_Sample_Type
reports	O
of	O
oropharyngeal	O
cancers	O
tested	O
for	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
were	O
reviewed	O
.	O

Patients	O
with	O
lymphoma	O
were	O
excluded	O
.	O

Multivariable	O
logistic	O
regression	O
models	O
were	O
constructed	O
.	O

All	O
statistical	O
tests	O
were	O
two	O
-	O
sided	O
.	O
Of	O
34	O
545	O
cancer	O
patients	O
tested	O
for	O
HCV	O
antibodies	O
,	O
409	B-Study_Cohort
case	I-Study_Cohort
subjects	I-Study_Cohort
(	I-Study_Cohort
164	I-Study_Cohort
oropharyngeal	I-Study_Cohort
and	I-Study_Cohort
245	I-Study_Cohort
nonoropharyngeal	I-Study_Cohort
)	I-Study_Cohort
and	O
694	O
control	O
subjects	O
(	O
378	O
lung	O
,	O
168	O
esophagus	O
,	O
and	O
148	O
urinary	O
bladder	O
)	O
were	O
studied	O
.	O

The	O
prevalence	B-Incidence_or_Prevalence
of	O
HCV	O
seropositivity	O
was	O
higher	O
in	O
oropharyngeal	O
cancer	O
patients	O
(	O
14	O
.	O
0	O
%	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
=	O
8	O
.	O
7	O
%	O
to	O
19	O
.	O
4	O
%	O
,	O
vs	O
6	O
.	O
5	O
%	O
,	O
95	O
%	O
CIâ€‰=â€‰4	O
.	O
6	O
%	O
to	O
8	O
.	O
3	O
%	O
)	O
,	O
particularly	O
HPV	O
-	O
positive	O
oropharyngeal	O
cancer	O
patients	O
(	O
16	O
.	O
9	O
%	O
,	O
95	O
%	O
CIâ€‰=â€‰8	O
.	O
7	O
%	O
to	O
24	O
.	O
9	O
%	O
,	O
vs	O
6	O
.	O
5	O
%	O
,	O
95	O
%	O
CIâ€‰=â€‰4	O
.	O
6	O
%	O
to	O
8	O
.	O
3	O
%	O
)	O
,	O
and	O
nonoropharyngeal	O
HNC	O
patients	O
(	O
20	O
.	O
0	O
%	O
,	O
95	O
%	O
CIâ€‰=â€‰14	O
.	O
9	O
%	O
to	O
25	O
.	O
0	O
%	O
,	O
vs	O
6	O
.	O
5	O
%	O
,	O
95	O
%	O
CIâ€‰=â€‰4	O
.	O
6	O
%	O
to	O
8	O
.	O
3	O
%	O
)	O
than	O
in	O
control	O
subjects	O
.	O

Adjusted	O
models	O
showed	O
a	O
statistically	O
significant	O
association	O
of	O
HCV	O
seropositivity	O
with	O
nonoropharyngeal	O
(	O
except	O
nasopharyngeal	O
)	O
HNCs	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
=	O
2	O
.	O
85	O
,	O
95	O
%	O
CIâ€‰=â€‰1	O
.	O
38	O
to	O
5	O
.	O
88	O
)	O
and	O
HPV	O
-	O
positive	O
oropharyngeal	O
cancers	O
(	O
ORâ€‰=â€‰2	O
.	O
97	O
,	O
95	O
%	O
CIâ€‰=â€‰1	O
.	O
31	O
to	O
6	O
.	O
76	O
)	O
.	O
HCV	O
is	O
associated	O
with	O
nonoropharyngeal	O
(	O
except	O
nasopharyngeal	O
)	O
and	O
HPV	O
-	O
positive	O
oropharyngeal	O
HNCs	O
.	O

Further	O
studies	O
are	O
required	O
to	O
explore	O
the	O
possible	O
interaction	O
between	O
HCV	O
and	O
HPV	O
,	O
and	O
the	O
association	O
between	O
HCV	O
and	O
other	O
HPV	O
-	O
related	O
malignancies	O
.	O

%	O
%	O
METHODS	O

Study	O
Design	O
and	O
Patient	O
Population	O

We	O
conducted	O
a	O
case	B-Study_Type
-	I-Study_Type
control	I-Study_Type
study	I-Study_Type
.	I-Study_Type

After	O
obtaining	O
approval	O
from	O
our	O
institution’s	O
institutional	O
review	O
“board”	O
(	O
IRB	O
)	O
,	O
we	O
identified	O
medical	O
records	O
of	O
all	O
cancer	B-Study_Cohort
patients	I-Study_Cohort
age	I-Study_Cohort
18	I-Study_Cohort
years	I-Study_Cohort
old	I-Study_Cohort
and	I-Study_Cohort
older	I-Study_Cohort
at	I-Study_Cohort
cancer	I-Study_Cohort
diagnosis	I-Study_Cohort
seen	I-Study_Cohort
at	I-Study_Cohort
our	I-Study_Cohort
institution	I-Study_Cohort
and	I-Study_Cohort
tested	I-Study_Cohort
for	I-Study_Cohort
HCV	I-Study_Cohort
antibodies	I-Study_Cohort
between	O
June	B-Study_Time
1	I-Study_Time
,	I-Study_Time
2004	I-Study_Time
,	I-Study_Time
and	I-Study_Time
May	I-Study_Time
31	I-Study_Time
,	I-Study_Time
2014	I-Study_Time
.	I-Study_Time

A	O
waiver	O
for	O
the	O
written	O
informed	O
consent	O
was	O
obtained	O
from	O
the	O
IRB	O
because	O
this	O
study	O
was	O
a	O
retrospective	O
evaluation	O
of	O
the	O
pa	O
-	O
tients’	O
information	O
and	O
did	O
not	O
involve	O
more	O
than	O
minimal	O
risk	O
to	O
the	O
subjects	O
.	O

Using	O
the	O
Clinical	O
Informatics	O
database	O
,	O
we	O
ob	O
-	O
tained	O
data	O
on	O
the	O
sites	O
and	O
histopathological	O
diagnoses	O
of	O
can	O
-	O
cers	O
in	O
these	O
patients	O
.	O

We	O
selected	O
patients	O
with	O
HNCs	O
as	O
case	O
subjects	O
and	O
divided	O
them	O
into	O
two	O
groups	O
with	O
different	O
cancer	O
etiologies	O
:	O
patients	O
with	O
oropharyngeal	O
and	O
patients	O
with	O
non	O
-	O
oropharyngeal	O
(	O
oral	O
cavity	O
,	O
nasopharynx	O
,	O
hypopharynx	O
,	O
and	O
lar	O
-	O
ynx	O
)	O
cancers	O
(	O
)	O
.	O

The	O
tumor	O
sites	O
and	O
International	O
Classification	O
of	O
Diseases	O
for	O
Oncology	O
topographical	O
codes	O
for	O
the	O
case	O
subjects	O
are	O
presented	O
in	O
Supplementary	O
Table	O
1	O
(	O
avail	O
-	O
able	O
online	O
)	O
(	O
)	O
.	O

As	O
smoking	O
is	O
a	O
major	O
risk	O
factor	O
for	O
HNCs	O
(	O
)	O
,	O
we	O
selected	O
as	O
the	O
control	O
group	O
patients	O
with	O
three	O
major	O
smoking	O
-	O
associated	O
cancers—lung	O
,	O
esophagus	O
,	O
and	O
urinary	O
bladder	O
(	O
)	O
—to	O
balance	O
the	O
distribution	O
of	O
smoking	O
-	O
related	O
risk	O
factors	O
between	O
case	O
and	O
control	O
groups	O
(	O
)	O
.	O

All	O
cancer	O
di	O
-	O
agnoses	O
were	O
histopathologically	O
confirmed	O
at	O
our	O
center	O
.	O

Because	O
HCV	O
infection	O
is	O
associated	O
with	O
B	O
-	O
cell	O
non	O
-	O
Hodgkin’s	O
lymphoma	O
,	O
we	O
excluded	O
patients	O
with	O
lymphoma	O
.	O

Ascertainment	O
of	O
Exposures	O
and	O
Covariates	O

Patients	O
with	O
HCV	O
were	O
identified	O
using	O
International	O
Classification	O
of	O
Diseases	O
(	O
ninth	O
revision	O
)	O
codes	O
for	O
HCV	O
infection	O
(	O
070	O
.	O
41	O
,	O
070	O
.	O
44	O
,	O
070	O
.	O
51	O
,	O
070	O
.	O
54	O
,	O
070	O
.	O
70	O
,	O
070	O
.	O
71	O
,	O
or	O
V02	O
.	O
62	O
)	O
,	O
and	O
the	O

diagnosis	O
was	O
verified	O
by	O
medical	O
records	O
review	O
.	O

HCV	O
seroposi	O
-	O
tivity	O
was	O
defined	O
as	O
detectable	O
HCV	O
antibody	O
in	O
serum	O
.	O

Patients	O
were	O
tested	O
for	O
HCV	O
antibodies	O
using	O
the	O
ORTHO	O
HCV	O
Version	O
3	O
.	O
0	O
ensyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
;	O
Ortho	O
-	O
Clinical	O
Diagnostics	O
,	O
Raritan	O
,	O
NJ	O
)	O
from	O
2004	O
to	O
2007	O
and	O
the	O
ABBOTT	O
PRISM	O
HCV	O
assay	O
(	O
Abbott	O
Park	O
,	O
IL	O
)	O
from	O
2007	O
to	O
2014	O
(	O
screening	O
tests	O
were	O
changed	O
in	O
2007	O
by	O
the	O
institution	O
)	O
.	O

Both	O
tests	O
are	O
US	O
Food	O
and	O
Drug	O
Administration–approved	O
,	O
commercially	O
available	O
assays	O
with	O
specificity	O
greater	O
than	O
99	O
%	O
(	O
,	O
)	O
.	O

HCV	O
infection	O
was	O
defined	O
as	O
detectable	O
HCV	O
RNA	O
in	O
serum	O
.	O

HCV	O
RNA	O
was	O
tested	O
by	O
Cobas	O
TaqMan	O
HCV	O
Monitor	O
version	O
1	O
.	O
0	O
or	O
2	O
.	O
0	O
assay	O
(	O
Roche	O
Molecular	O
Systems	O
,	O
Branchburg	O
,	O
NJ	O
)	O
.	O

Data	O
on	O
co	O
-	O
infections	O
with	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
and	O
HIV	O
were	O
also	O
obtained	O
.	O

HBV	O
ex	O
-	O
posure	O
was	O
defined	O
as	O
positivity	O
for	O
HBV	O
core	O
antibody	O
,	O
and	O
HIV	O
infection	O
was	O
defined	O
as	O
positivity	O
for	O
HIV	O
antibody	O
.	O

From	O
the	O
standardized	O
questionnaire	O
administered	O
to	O
all	O
pa	O
-	O
tients	O
at	O
their	O
first	O
visit	O
at	O
our	O
institution	O
,	O
we	O
extracted	O
data	O
on	O
de	O
-	O
mographics	O
,	O
including	O
birth	O
year	O
,	O
highest	O
education	O
level	O

(	O
surrogate	O
for	O
socioeconomic	O
status	O
)	O
,	O
cigarette	O
smoking	O
,	O
and	O
alco	O
-	O
hol	O
consumption	O
.	O

Smoking	O
-	O
related	O
information	O
collected	O
included	O
smoking	O
status	O
(	O
never	O
,	O
former	O
,	O
or	O
current	O
smoker	O
)	O
,	O
age	O
at	O
starting	O
/	O
quitting	O
smoking	O
,	O
number	O
of	O
years	O
of	O
smoking	O
,	O
number	O
of	O
ciga	O
-	O
rettes	O
smoked	O
per	O
day	O
,	O
and	O
duration	O
of	O
smoking	O
in	O
pack	O
-	O
years	O
(	O
number	O
of	O
cigarette	O
packs	O
smoked	O
per	O
day	O
multiplied	O
by	O
number	O
of	O
years	O
smoked	O
)	O
.	O

Never	O
smokers	O
were	O
those	O
who	O
smoked	O
fewer	O
than	O
100	O
cigarettes	O
in	O
their	O
lifetime	O
.	O

Former	O
smokers	O
were	O
those	O
who	O
had	O
quit	O
at	O
least	O
one	O
year	O
before	O
cancer	O
diagnosis	O
.	O

Alcohol	O
-	O
re	O
-	O
lated	O
information	O
collected	O
included	O
drinking	O
status	O
(	O
never	O
,	O
for	O
-	O
mer	O
,	O
or	O
current	O
drinker	O
)	O
,	O
age	O
at	O
starting	O
/	O
quitting	O
alcohol	O
drinking	O
,	O
number	O
of	O
years	O
of	O
drinking	O
,	O
and	O
number	O
of	O
alcoholic	O
drinks	O
con	O
-	O
sumed	O
per	O
week	O
,	O
with	O
a	O
standard	O
drink	O
defined	O
as	O
4	O
ounces	O
for	O
wine	O
,	O
12	O
ounces	O
for	O
beer	O
,	O
and	O
1	O
.	O
5	O
ounces	O
for	O
hard	O
liquor	O
(	O
)	O
.	O

Pathology	O
reports	O
of	O
all	O
case	O
subjects	O
were	O
reviewed	O
in	O
our	O
center	O
to	O
determine	O
whether	O
tumors	O
were	O
positive	O
for	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
or	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
.	O

HPV	O
p16	B-HPV_Lab_Technique
pro	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
tein	I-HPV_Lab_Technique
expression	I-HPV_Lab_Technique
was	I-HPV_Lab_Technique
examined	I-HPV_Lab_Technique
using	I-HPV_Lab_Technique
immunohistochemistry	I-HPV_Lab_Technique
,	O
and	O
the	O
presence	O
of	O
high	O
-	O
risk	O
HPV	O
types	O
(	O
16	O
,	O
18	O
,	O
31	O
,	O
33	O
,	O
35	O
,	O
39	O
,	O
45	O
,	O

51	O
,	O
52	O
,	O
56	O
,	O
58	O
,	O
and	O
66	O
)	O
was	O
examined	O
using	O
in	B-HPV_Lab_Technique
situ	I-HPV_Lab_Technique
hybridization	I-HPV_Lab_Technique
(	O
)	O
.	O

Oropharyngeal	O
cancers	O
were	O
considered	O
HPV	O
positive	O
if	O
high	O
-	O
risk	O
HPV	O
tumors	O
were	O
positive	O
for	O
p16	O
.	O

Tumors	O
were	O
tested	O
for	O
EBV	O
-	O
encoded	O
RNA	O
using	O
in	B-HPV_Lab_Technique
situ	I-HPV_Lab_Technique
hybridization	I-HPV_Lab_Technique
(	O
)	O
.	O

Statistical	O
Analyses	O

We	O
conducted	O
different	O
analyses	O
to	O
determine	O
whether	O
HCV	O
se	O
-	O
ropositivity	O
was	O
associated	O
with	O
oropharyngeal	O
or	O
nonorophar	O
-	O
yngeal	O
HNCs	O
.	O

We	O
separately	O
compared	O
characteristics	O
of	O
the	O
two	O
case	O
groups	O
and	O
the	O
control	O
group	O
.	O

Categorical	O
variables	O
were	O
compared	O
using	O
Pearson’s	O
chi	O
-	O
squared	O
test	O
or	O
Fisher’s	O
ex	O
-	O
act	O
test	O
,	O
and	O
continuous	O
variables	O
were	O
compared	O
using	O
Wilcoxon	O
rank	O
-	O
sum	O
test	O
(	O
for	O
non	O
-	O
normal	O
distributions	O
)	O
.	O

Univariate	O
logistic	O
regression	O
analysis	O
was	O
conducted	O
to	O
ex	O
-	O
amine	O
the	O
association	O
between	O
HCV	O
seropositivity	O
and	O
the	O
case	O
group	O
.	O

Potential	O
confounders	O
were	O
assessed	O
by	O
introducing	O
them	O
in	O
the	O
model	O
,	O
and	O
we	O
included	O
variables	O
that	O
changed	O
the	O
estimates	O
by	O
10	O
%	O
or	O
more	O
in	O
the	O
adjusted	O
model	O
.	O

Final	O
adjusted	O
multivariable	O
logistic	O
regression	O
models	O
were	O
constructed	O
and	O
the	O
most	O
parsimonious	O
models	O
selected	O
using	O
Akaike	O
informa	O
-	O
tion	O
criterion	O
.	O

We	O
reported	O
the	O
effect	O
sizes	O
as	O
odds	O
ratios	O
(	O
ORs	O
)	O
and	O
corresponding	O
95	O
%	O
confidence	O
intervals	O
(	O
CIs	O
)	O
and	O
P	O
values	O
.	O

To	O
account	O
for	O
different	O
pathogenesis	O
of	O
cancers	O
,	O
we	O
conducted	O
subgroup	O
analyses	O
to	O
determine	O
the	O
associations	O
between	O
HCV	O
se	O
-	O
ropositivity	O
and	O
oropharyngeal	O
cancers	O
,	O
according	O
to	O
HPV	O
status	O
,	O
and	O
nasopharyngeal	O
cancers	O
.	O

We	O
performed	O
sensitivity	O
analyses	O
and	O
evaluated	O
the	O
associations	O
by	O
including	O
only	O
patients	O
with	O
HCV	O
infection	O
.	O

Finally	O
,	O
in	O
an	O
exploratory	O
analysis	O
,	O
we	O
fit	O
separate	O
unconditional	O
logistic	O
regression	O
models	O
for	O
each	O
HNC	O
subsite	O
and	O
adjusted	O
for	O
potential	O
confounders	O
.	O

We	O
corrected	O
the	O
P	O
values	O
for	O
multiple	O
comparisons	O
using	O
a	O
false	O
-	O
discovery	O
rate	O
of	O
10	O
%	O
accord	O
-	O
ing	O
to	O
the	O
Benjamini	O
and	O
Hochberg	O
method	O
(	O
)	O
.	O

All	O
statistical	O
tests	O
were	O
two	O
-	O
sided	O
,	O
and	O
P	O
values	O
of	O
less	O
than	O

.	O
05	O
were	O
considered	O
statistically	O
significant	O
.	O

Statistical	O
analyses	O
were	O
conducted	O
using	O
Stata	O
/	O
IC	O
software	O
,	O
version	O
13	O
.	O
0	O
(	O
StataCorp	O
LP	O
,	O
College	O
Station	O
,	O
TX	O
)	O
.	O

